Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational stud
Our findings indicate a low rate of inpatient systemic therapy for patients with mUC in Italy (driven by older age, female sex, and high comorbidity burden), with a large economic burden despite a high nontreatment rate. Although this study provides a partial capture of the treatment pathway in Italy, the results are consistent with other European studies with similar designs and highlight the need to better identify the reasons for not administering inpatient systemic chemotherapy and/or radiotherapy.
Authors
- Cécile Pacheco
- Martina Furegato
- Matteo Scortichini
- Seham Issa (ORCID: https://orcid.org/0000-0002-1854-1839)
- Paolo Sciattella (ORCID: https://orcid.org/0000-0002-8364-1895)
- Melissa Kirker
- Reyhan Hasanova (ORCID: https://orcid.org/0000-0002-2088-7003)
- Mairead Kearney
- Norbek Gharibian
- Allison Thompson
- Francesco Saverio Mennini
Institutions
- University of Rome Tor Vergata (IT)
- Merck KGaA, Darmstadt (Germany) (DE)
- Pfizer (United States) (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1186/s12885-024-13075-y
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer